login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
VERACYTE INC (VCYT) Stock News
USA
- NASDAQ:VCYT -
US92337F1075
-
Common Stock
38.43
USD
-0.85 (-2.16%)
Last: 11/18/2025, 1:31:33 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
VCYT Latest News, Press Relases and Analysis
All
Press Releases
19 days ago - By: Chartmill
Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Biotech
5 days ago - By: Zacks Investment Research
- Mentions:
UHS
EXAS
ENSG
Ensign Group Shares Decline 2.2% Despite Q3 Earnings Beat
7 days ago - By: Zacks Investment Research
- Mentions:
UHS
EXAS
EHC
Encompass Health Shares Down 8% Despite Q3 Earnings & Revenue Beat
7 days ago - By: Zacks Investment Research
- Mentions:
BSX
IDXX
MEDP
VCYT Stock Gains on Q3 Earnings and Revenue Beat, '25 View Up
8 days ago - By: Zacks Investment Research
- Mentions:
UHS
THC
EXAS
Tenet Healthcare Shares Down 5% Despite Q3 Earnings Beat
12 days ago - By: Zacks Investment Research
- Mentions:
UHS
MCK
MD
Pediatrix Medical Q3 Earnings Beat Estimates on Declining Expenses
12 days ago - By: Veracyte, Inc.
Veracyte to Participate in Upcoming Investor Conferences
13 days ago - By: Benzinga
- Mentions:
QS
FUBO
MRVL
LMND
...
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday
14 days ago - By: Zacks Investment Research
- Mentions:
AVNS
Veracyte (VCYT) Q3 Earnings and Revenues Beat Estimates
14 days ago - By: Veracyte, Inc.
Veracyte Announces Third Quarter 2025 Financial Results
14 days ago - By: Benzinga
- Mentions:
KURA
SEE
HRMY
FOLD
...
Earnings Scheduled For November 4, 2025
15 days ago - By: Veracyte, Inc.
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
18 days ago - By: Zacks Investment Research
- Mentions:
EW
PODD
PAHC
EW Stock Gains on Q3 Earnings and Revenue Beat, Margins Crash
19 days ago - By: Zacks Investment Research
- Mentions:
ALGN
PODD
PAHC
ALGN Stock Up on Q3 Earnings and Revenue Beat, Margins Crash
20 days ago - By: Zacks Investment Research
- Mentions:
PODD
CHE
PAHC
CHE Stock Falls on Q3 Earnings and Revenue Miss, Margins Crash
25 days ago - By: Zacks Investment Research
- Mentions:
PODD
PAHC
ITGR
ITGR Shares Down Despite Q3 Earnings & Revenues Beat Estimates
a month ago - By: Veracyte, Inc.
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
2 months ago - By: Veracyte, Inc.
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
2 months ago - By: Veracyte, Inc.
Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
2 months ago - By: Veracyte, Inc.
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
3 months ago - By: Zacks Investment Research
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
3 months ago - By: Zacks Investment Research
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today
3 months ago - By: Veracyte, Inc.
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
3 months ago - By: Veracyte, Inc.
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
3 months ago - By: Zacks Investment Research
- Mentions:
NEO
TEM
Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership
3 months ago - By: Veracyte, Inc.
Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
3 months ago - By: Zacks Investment Research
Here's Why Veracyte (VCYT) is a Strong Momentum Stock
3 months ago - By: Zacks Investment Research
Here's Why Veracyte (VCYT) is a Strong Growth Stock
3 months ago - By: Zacks Investment Research
- Mentions:
CAH
MEDP
WGS
VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up
3 months ago - By: The Motley Fool
Veracyte (VCYT) Q2 Revenue Jumps 14%
3 months ago - By: Zacks Investment Research
- Mentions:
SGHT
Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates
3 months ago - By: Veracyte, Inc.
Veracyte Announces Second Quarter 2025 Financial Results
Please enable JavaScript to continue using this application.